Guardian Net Income From Continuing Ops from 2010 to 2024

GRDN Stock   24.94  0.02  0.08%   
Guardian Pharmacy Net Income From Continuing Ops yearly trend continues to be very stable with very little volatility. Net Income From Continuing Ops is likely to grow to about 40 M this year. During the period from 2010 to 2024, Guardian Pharmacy Net Income From Continuing Ops quarterly data regression pattern had sample variance of 34.4 T and median of  29,660,000. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
2010-12-31
Previous Quarter
37.7 M
Current Value
40 M
Quarterly Volatility
5.9 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Guardian Pharmacy financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Guardian Pharmacy's main balance sheet or income statement drivers, such as Interest Expense of 2.4 M, Selling General Administrative of 147.1 M or Total Revenue of 957.9 M, as well as many indicators such as . Guardian financial statements analysis is a perfect complement when working with Guardian Pharmacy Valuation or Volatility modules.
  
Check out the analysis of Guardian Pharmacy Correlation against competitors.

Latest Guardian Pharmacy's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Guardian Pharmacy Services, over the last few years. It is Guardian Pharmacy's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Guardian Pharmacy's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Guardian Net Income From Continuing Ops Regression Statistics

Arithmetic Mean32,129,528
Geometric Mean31,722,220
Coefficient Of Variation18.26
Mean Deviation4,129,112
Median29,660,000
Standard Deviation5,865,900
Sample Variance34.4T
Range21.3M
R-Value0.59
Mean Square Error24.3T
R-Squared0.34
Significance0.02
Slope768,716
Total Sum of Squares481.7T

Guardian Net Income From Continuing Ops History

202440 M
202337.7 M
202249.7 M
202128.3 M

About Guardian Pharmacy Financial Statements

Guardian Pharmacy investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Guardian Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Income From Continuing Ops37.7 M40 M

Pair Trading with Guardian Pharmacy

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Guardian Pharmacy position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Guardian Pharmacy will appreciate offsetting losses from the drop in the long position's value.

Moving together with Guardian Stock

  0.7EHAB EnhabitPairCorr

Moving against Guardian Stock

  0.71CCM Concord Medical ServicesPairCorr
  0.42AMS American Shared HospitalPairCorr
  0.4NIVF NewGenIvf GroupPairCorr
  0.31TOI Oncology InstitutePairCorr
The ability to find closely correlated positions to Guardian Pharmacy could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Guardian Pharmacy when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Guardian Pharmacy - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Guardian Pharmacy Services, to buy it.
The correlation of Guardian Pharmacy is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Guardian Pharmacy moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Guardian Pharmacy moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Guardian Pharmacy can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Guardian Pharmacy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Guardian Pharmacy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Guardian Pharmacy Services, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Guardian Pharmacy Services, Stock:
Check out the analysis of Guardian Pharmacy Correlation against competitors.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Retail space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardian Pharmacy. If investors know Guardian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardian Pharmacy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Guardian Pharmacy is measured differently than its book value, which is the value of Guardian that is recorded on the company's balance sheet. Investors also form their own opinion of Guardian Pharmacy's value that differs from its market value or its book value, called intrinsic value, which is Guardian Pharmacy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardian Pharmacy's market value can be influenced by many factors that don't directly affect Guardian Pharmacy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardian Pharmacy's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardian Pharmacy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardian Pharmacy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.